New directions in cancer therapy

Helix BioPharma Corporation is a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. Helix is currently listed on TSX and FSE under the symbol “HBP”

home_image

DOS47

Our most innovative technological platform for the treatment of solid tumors

News

June 27, 2016

STREAM Medical University of Warsaw Poland

Therapeutic Strategy Against Tumour Acidity Induced Immune-Suppression

March 29, 2016

Helix BioPharma Corp. Announces CEO Change

(Aurora, Ontario) – Helix BioPharma Corp. (hereinafter defined as “Helix” or the “Company” and listed on TSX & FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Zbigniew Markowski will be stepping down, for personal and family reasons, from his positions as Chief Executive Officer of Helix BioPharma Corp and Chairman of Helix Polska, effective March 29th, 2016. Stepping into both roles, effective immediately, will be Dr. Sven Rohmann.

March 8, 2016

Helix BioPharma Corp. Reports on Advancement of Its L-DOS47 Phase I/II Study in Poland

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Registration Office of Medicinal Products, Medical Devices and Biocides in Poland and the Bioethics Committee has approved an amendment to the Phase I/II study (“LDOS002”) defining the dose and dosing regimen for the Phase II study.